EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

The Uncharted Territory of the New Obesity Drugs in Users Without Obesity: A Sociomedical Perspective

Fernanda Baeza Scagliusi iD, Bruno Gualano iD, Pernille Andreassen, Cindi SturtzSreetharan, Sissel Due Jensen, Alexandra Brewis

Obesity · 2026-09 · 34 (S2) · 9-12

DOI: 10.1002/oby.70069 ↗

At a glance

Journal article in Obesity, published online on 2025-11-12. Written by Fernanda Baeza Scagliusi and 5 co-authors. Institution: Department of Nutrition, Research Group in Eating, Corporalities and Culture (GPAC), University of São Paulo School of Public Health, São Paulo, São …. Major MEDLINE topics: Anti-Obesity Agents, Obesity, Off-Label Use, Glucagon-Like Peptide-1 Receptor Agonists. Cited 3 times so far (Crossref); 10 references. The full text is freely available (open access, CC BY 4.0). Funded by: Conselho Nacional de Desenvolvimento Científico e Tecnológico.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

The off‐label use of glucagon‐like peptide‐1 receptor agonists (GLP‐1ra) among people without obesity and/or diabetes is rapidly expanding, despite a lack of clinical justification or safety data in this population. This Perspective explores the sociomedical dimensions of this trend, highlighting key research gaps and emerging hypotheses around the off‐label use of GLP‐1ra to an individual goal of slimness rather than health. We propose that off‐label GLP‐1ra use by people with normative or mildly elevated weight reveals deeper tensions between scientific progress, stigma, and cultural ideals of the body. Understanding this phenomenon requires moving beyond biomedical efficacy to interrogate the psychological, behavioral, and sociopolitical implications of pharmacological thinness. Cross‐cultural and intersectional approaches from the social sciences are key to understanding this emergent phenomenon.

Subjects

MeSH terms (MEDLINE)

Anti-Obesity AgentsObesityOff-Label UseGlucagon-Like Peptide-1 Receptor AgonistsHumansSocial Stigma

Author keywords

anti‐obesity drugsobesityoff‐label useslimnesssociomedical aspects

Substances

Anti-Obesity AgentsGlucagon-Like Peptide-1 Receptor Agonists

Authors and institutions

  • Department of Nutrition, Research Group in Eating, Corporalities and Culture (GPAC), University of São Paulo School of Public Health, São Paulo, São Paulo, Brazil.
  • Department of Clinical Medicine, Center for Lifestyle Medicine (CMEV), University of São Paulo School of Medicine, São Paulo, São Paulo, Brazil.
  • The Danish National Center for Obesity, Aarhus University Hospital, Aarhus, Jutland, Denmark.
  • Arizona State University, School of Human Evolution and Social Change, Center for Global Health, Tempe, Arizona, USA.
  • Department of Public Health, Aarhus University, Aarhus, Jutland, Denmark.
  • Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Jutland, Denmark.

ORCID profiles: Fernanda Baeza Scagliusi, Bruno Gualano

Funding

  • Conselho Nacional de Desenvolvimento Científico e Tecnológico

Cite

APA

Scagliusi, F. B., Gualano, B., Andreassen, P., SturtzSreetharan, C., Jensen, S. D., & Brewis, A. (2026). The Uncharted Territory of the New Obesity Drugs in Users Without Obesity: A Sociomedical Perspective. Obesity, 34(S2), 9-12. https://doi.org/10.1002/oby.70069

Vancouver

Scagliusi FB, Gualano B, Andreassen P, SturtzSreetharan C, Jensen SD, Brewis A. The Uncharted Territory of the New Obesity Drugs in Users Without Obesity: A Sociomedical Perspective. Obesity. 2026;34(S2):9-12. doi:10.1002/oby.70069

BibTeX
@article{Scagliusi2026,
  author = {Scagliusi, Fernanda Baeza and Gualano, Bruno and Andreassen, Pernille and SturtzSreetharan, Cindi and Jensen, Sissel Due and Brewis, Alexandra},
  title = {The Uncharted Territory of the New Obesity Drugs in Users Without Obesity: A Sociomedical Perspective},
  journal = {Obesity},
  year = {2026},
  volume = {34},
  number = {S2},
  pages = {9--12},
  doi = {10.1002/oby.70069}
}
Start for free →